WeVote
Log In

Bill

Bill

HB 1088

Relating to the statute of limitations on a health care liability claim involving certain gender modification drugs provided to and procedures performed on a minor.

89th Legislature (2025) Introduced by Daniel Alders and 20 co-sponsors

Texas bill extends statute of limitations for medical malpractice claims against providers offering gender-affirming drugs and procedures to minors, potentially reducing treatment availability.

Committee report sent to Calendars
#civilremedies&liabilities(i0065) #genderidentity&expression(s0767) #malpractice--professionals(i0525) #minors--health&safety(i0533) #statutesoflimitations(s0065)
0
WeVote Research Nonpartisan
Bill Summary · HB 1088

Legislative bill overview

HB 1088 extends the statute of limitations for filing medical malpractice lawsuits against healthcare providers who provide gender-affirming medications or procedures to minors in Texas. The bill allows patients (or their representatives) to pursue claims beyond the standard limitation period, potentially indefinitely in some cases until the minor reaches adulthood plus additional years.

Why is this important

This bill directly affects access to gender-affirming care for transgender and non-binary minors in Texas by creating extended legal liability for providers. Healthcare providers may decline to offer these services due to prolonged legal exposure, reducing treatment options for families seeking this care. The bill also reflects broader national debate over whether such medical interventions for minors require additional legal protections and oversight.

Potential points of contention

  • Medical autonomy vs. protection: Supporters argue minors need extended legal recourse if they later regret treatment; opponents counter that extended liability periods may deter providers from offering care parents and doctors consider medically appropriate
  • Definition and scope: Unclear which drugs and procedures qualify, and whether this applies to established treatments (like puberty blockers used in pediatric endocrinology) or experimental interventions
  • Disparate impact: The targeted statute of limitations differs from other medical specialties, raising questions about whether gender-affirming care is being treated differently than comparable pediatric procedures

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.